Palvella presents positive Phase 3 SELVA and Phase 2 TOIVA data for QTORIN rapamycin

Palvella Therapeutics announced clinical trial results showing 100% of SELVA participants aged 6-11 years improved on primary endpoint, with QTORIN rapamycin demonstrating potential as first FDA-approved therapy for microcystic lymphatic malformations and cutaneous venous malformations. The data supports advancement toward potential regulatory approval for rare vascular diseases with no current approved treatments.